FDA: Diabetes drug may increase risk for leg and foot amputations

The Food and Drug Administration has issued a safety announcement warning patients and healthcare providers about the potential link between foot and leg amputations and use of the diabetes drug canagliflozin. Canagliflozin, which is sold under the brand names Invokana and Invokamet, is prescribed as a treatment for high blood sugar in type 2 diabetes patients. Invokamet is canagliflozin combined with metformin.

The Food and Drug Administration has issued a safety announcement warning patients and healthcare providers about the potential link between foot and leg amputations and use of the diabetes drug canagliflozin. Canagliflozin, which is sold under the brand names Invokana and Invokamet, is prescribed as a treatment for high blood sugar in type 2 diabetes patients. Invokamet is canagliflozin combined with metformin.

See the article here:
FDA: Diabetes drug may increase risk for leg and foot amputations